[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1220866A1 - 表達具有共同輕鏈的抗體的非人動物 - Google Patents

表達具有共同輕鏈的抗體的非人動物

Info

Publication number
HK1220866A1
HK1220866A1 HK16109169.8A HK16109169A HK1220866A1 HK 1220866 A1 HK1220866 A1 HK 1220866A1 HK 16109169 A HK16109169 A HK 16109169A HK 1220866 A1 HK1220866 A1 HK 1220866A1
Authority
HK
Hong Kong
Prior art keywords
light chain
human animals
common light
expressing antibodies
animals expressing
Prior art date
Application number
HK16109169.8A
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Sean Stevens
Samuel Davis
David R Buckler
Karolina A Hosiawa
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220866(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1220866A1 publication Critical patent/HK1220866A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16109169.8A 2011-04-25 2014-07-14 表達具有共同輕鏈的抗體的非人動物 HK1220866A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/093,156 US20120021409A1 (en) 2010-02-08 2011-04-25 Common Light Chain Mouse

Publications (1)

Publication Number Publication Date
HK1220866A1 true HK1220866A1 (zh) 2017-05-19

Family

ID=46000410

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16109169.8A HK1220866A1 (zh) 2011-04-25 2014-07-14 表達具有共同輕鏈的抗體的非人動物
HK14107153.2A HK1193718A1 (zh) 2011-04-25 2014-07-14 表達具有共同輕鏈的抗體的非人動物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14107153.2A HK1193718A1 (zh) 2011-04-25 2014-07-14 表達具有共同輕鏈的抗體的非人動物

Country Status (25)

Country Link
US (2) US20120021409A1 (zh)
EP (2) EP2989893B1 (zh)
JP (2) JP6393613B2 (zh)
KR (1) KR101995753B1 (zh)
CN (2) CN103596424B (zh)
AU (3) AU2012249953B2 (zh)
BR (1) BR112013027420A2 (zh)
CA (1) CA2846806A1 (zh)
CY (2) CY1117606T1 (zh)
DK (2) DK2701499T4 (zh)
ES (2) ES2743681T3 (zh)
HK (2) HK1220866A1 (zh)
HR (2) HRP20160484T4 (zh)
HU (2) HUE045401T2 (zh)
IL (1) IL228929A0 (zh)
LT (1) LT2989893T (zh)
MX (1) MX353609B (zh)
PL (2) PL2701499T5 (zh)
PT (1) PT2989893T (zh)
RS (2) RS59331B1 (zh)
RU (2) RU2614859C2 (zh)
SG (1) SG194466A1 (zh)
SI (2) SI2701499T2 (zh)
SM (2) SMT201900514T1 (zh)
WO (1) WO2012148873A2 (zh)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2798950B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HUE026229T2 (en) * 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG187673A1 (en) 2010-08-02 2013-03-28 Regeneron Pharma Mice that make binding proteins comprising vl domains
EP3434767A1 (en) 2010-11-30 2019-01-30 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
RS59929B1 (sr) 2011-02-25 2020-03-31 Regeneron Pharma Adam6 miševi
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
EP3128009B1 (en) 2011-09-19 2020-07-29 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR102148683B1 (ko) 2011-10-17 2020-08-27 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102186822B1 (ko) 2011-12-20 2020-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
US9301510B2 (en) 2012-03-16 2016-04-05 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with pH-dependent binding characteristics
CN104302171B (zh) 2012-03-16 2017-05-03 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
JP6185978B2 (ja) 2012-03-16 2017-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒスチジン操作された軽鎖抗体およびこれを作製するための遺伝子改変された非ヒト動物
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN107383197B (zh) 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
SI3597037T1 (sl) 2012-06-12 2021-07-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali, ki niso človek, z omejenimi lokusi težke verige imunoglobulina
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
MX355105B (es) 2013-02-20 2018-04-05 Regeneron Pharma Animales no humanos con secuencia de cadena pesada de inmunoglobulina con modificaciones.
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
SI3501272T1 (sl) * 2013-03-13 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo omejen repertoar lahke verige imunoglobulina
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
PL3046412T3 (pl) * 2013-09-18 2019-11-29 Regeneron Pharma Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania
DE112014004537T5 (de) * 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
MX2016012273A (es) 2014-03-21 2017-02-23 Regeneron Pharma Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
EP3221363B1 (en) 2014-11-21 2020-05-06 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
KR102582807B1 (ko) 2014-12-19 2023-09-26 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
WO2017035274A1 (en) * 2015-08-27 2017-03-02 Crystal Bioscience Inc. Transgenic animal for production of antibodies having a common light chain
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
JP6979955B2 (ja) 2016-01-13 2021-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 操作された重鎖可変領域を有する齧歯類
IL307425A (en) 2016-03-04 2023-12-01 Univ Rockefeller CD40 antibodies with increased agonistic activity
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
CA3023678A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR20230156162A (ko) * 2016-06-03 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
PE20191469A1 (es) 2016-10-13 2019-10-16 Massachusetts Inst Technology Anticuerpos que se unen a la proteina de envoltura el virus zika y usos de los mismos
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
MX2020013652A (es) 2018-06-14 2022-04-21 Regeneron Pharma Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
MX2021008796A (es) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos.
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP4010371A1 (en) 2019-08-08 2022-06-15 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022140219A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
MX2023007583A (es) 2020-12-23 2023-07-07 Regeneron Pharma Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
TW202430641A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
EP0546073B1 (en) * 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
KR100516133B1 (ko) * 1997-04-14 2005-09-21 마이크로메트 에이지 항-인간항원 수용체의 신규한 제조방법 및 용도
AU751659B2 (en) * 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
WO2004009618A2 (en) * 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2005538706A (ja) * 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
ES2350178T3 (es) * 2001-10-01 2011-01-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas.
EP2319301B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
WO2003061363A2 (en) * 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
CN1675245B (zh) * 2002-06-14 2011-01-12 免疫医疗公司 人源化单克隆抗体hPAM4
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2583550A1 (en) * 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
EP3456190B1 (en) * 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
AU2010252939B2 (en) * 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
HUE026229T2 (en) * 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи

Also Published As

Publication number Publication date
PT2989893T (pt) 2019-09-23
IL228929A0 (en) 2013-12-31
AU2012249953B2 (en) 2016-01-28
HUE027949T2 (en) 2016-11-28
SI2989893T1 (sl) 2019-10-30
RU2013152221A (ru) 2015-05-27
SMT201600133B (it) 2016-07-01
NZ617158A (en) 2016-04-29
HRP20160484T4 (hr) 2021-12-10
SMT201900514T1 (it) 2019-11-13
BR112013027420A2 (pt) 2016-08-09
PL2701499T3 (pl) 2017-03-31
ES2573828T3 (es) 2016-06-10
EP2701499A2 (en) 2014-03-05
ES2743681T3 (es) 2020-02-20
KR20140024909A (ko) 2014-03-03
HRP20191680T1 (hr) 2019-12-13
RU2017108634A (ru) 2019-01-22
CN105884887A (zh) 2016-08-24
EP2701499B9 (en) 2016-05-18
HRP20160484T1 (hr) 2016-06-03
CN103596424A (zh) 2014-02-19
SI2701499T1 (sl) 2016-10-28
JP6393613B2 (ja) 2018-09-19
MX2013012500A (es) 2014-02-03
RS54831B2 (sr) 2021-12-31
US20150313193A1 (en) 2015-11-05
DK2701499T3 (en) 2016-05-23
JP6522557B2 (ja) 2019-05-29
RS59331B1 (sr) 2019-10-31
ES2573828T5 (es) 2022-02-28
CA2846806A1 (en) 2012-11-01
AU2016202609A2 (en) 2017-02-02
KR101995753B1 (ko) 2019-07-03
HUE045401T2 (hu) 2019-12-30
AU2018236913A1 (en) 2018-10-25
WO2012148873A4 (en) 2013-03-14
DK2989893T3 (da) 2019-09-09
LT2989893T (lt) 2019-09-10
PL2989893T3 (pl) 2019-12-31
US20120021409A1 (en) 2012-01-26
PL2701499T5 (pl) 2021-12-13
RU2614859C2 (ru) 2017-03-29
CY1122036T1 (el) 2020-10-14
EP2989893A1 (en) 2016-03-02
WO2012148873A3 (en) 2013-02-07
HK1193718A1 (zh) 2014-10-03
AU2012249953A1 (en) 2013-05-02
WO2012148873A2 (en) 2012-11-01
EP2701499B8 (en) 2016-03-16
EP2989893B1 (en) 2019-06-19
DK2701499T4 (da) 2021-11-15
EP2701499B1 (en) 2016-02-10
CN103596424B (zh) 2016-01-20
JP2016178948A (ja) 2016-10-13
JP2014516518A (ja) 2014-07-17
MX353609B (es) 2018-01-18
EP2701499B2 (en) 2021-08-18
AU2016202609A1 (en) 2016-05-19
SI2701499T2 (sl) 2022-01-31
AU2016202609B2 (en) 2018-07-12
CY1117606T1 (el) 2017-04-26
SG194466A1 (en) 2013-12-30
RS54831B1 (sr) 2016-10-31

Similar Documents

Publication Publication Date Title
HRP20160484T1 (hr) Životinje koje izražavaju antitijela sa zajedničkim lakim lancem
IL266268B (en) Mice with humanized light chain
HK1208994A1 (zh) 使用共同輕鏈製備完全人雙特異性抗體的方法
HK1202560A1 (zh) 輕鏈橋連的雙特異性抗體
IL222197A0 (en) CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
EP2744352A4 (en) MULTIPLE TEXTURED ANIMAL TREATMENTS
GB201712535D0 (en) Chain tension sensor
GB201110528D0 (en) A pet toy
GB201212970D0 (en) Chain tension sensor
GB2496094B (en) Automatic Chain Oiler
GB201121369D0 (en) A chain
GB201120846D0 (en) A lure
AU339792S (en) Driving light A